Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
International Journal of Hematology
Published in: International Journal of Hematology 4/2011

01-10-2011 | Letter to the Editor

Type 2B-like acquired von Willebrand syndrome

Authors: Toshio Shigekiyo, Etsuko Sekimoto, Atsuhisa Shirakami, Hiroshi Yamaguchi, Hironobu Shibata, Shuji Ozaki, Kazuya Kanda, Seiya Saito, Nobuo Satake, Osamu Fujino

Published in: International Journal of Hematology | Issue 4/2011

Login to get access

Excerpt

More than 300 cases of acquired von Willebrand syndrome (AVWS) have been reported, but it is thought that this number reflects only the tip of the iceberg [1]. Data from an international registry has shown that AVWS may be associated with lymphoproliferative (48%) or myeloproliferative (15%) disorders, neoplasia (5%), immunological (2%), cardiovascular (21%) and miscellaneous conditions (9%) [2]. AVWS usually mimics von Willebrand disease (VWD) type 1 or 2A [3, 4]. To our knowledge, only two cases of type 2B-like AVWS have been reported previously [4, 5]. They were both associated with plasma cell dyscrasia. Here we show a new case of type 2B-like AVWS. …
Literature
1.
Federici AB. Acquired von Willebrand syndrome: is it an extremely rare disorder or do we see only the tip of the iceberg? J Thromb Haemost. 2008;6:565–8.CrossRefPubMed
2.
Federici AB, Rand JH, Bucciarelli P, Budde U, van Genderen PJ, Mohri H, Meyer D, Rodeghiero F, Sadler JE. Acquired von Willebrand syndrome: data from an international registry. On behalf of the subcommittee on von Willebrand factor. Thromb Haemost. 2000;84:345–9.PubMed
3.
Veyradier A, Jenkins CSP, Fressinaud E, Meyer D. Acquired von Willebrand syndrome: from pathophysiology to management. Thromb Haemost. 2000;84:175–82.PubMed
4.
Karger R, Weippert-Kretschmer M, Budde U, Kretschmer V. Diagnosis and therapeutic management in a patient with type 2B-like acquired von Willebrand syndrome. Blood Coagul Fibrinolysis. 2011;22:144–7.CrossRefPubMed
5.
Drouin J, Lillicrap DP, Izaguirre CA, Sutherland M, Windsor S, Benford K, Hoogendorn H, Giles AR. Absence of a bleeding tendency in severe acquired von Willebrand’s disease. The role of platelet von Willebrand factor in maintaining normal hemostasis. Am J Clin Pathol. 1989;92:471–8.CrossRefPubMed
6.
Mancuso DJ, Tuley EA, Westfield LA, Lester-Mancuso TL, Le Beau MM, Sorace JM, Sadler JE. Human von Willebrand factor gene and pseudogene: structural analysis and differentiation by polymerase chain reaction. Biochemistry. 1991;30:253–69.CrossRefPubMed
7.
Wenger RH, Kieffer N, Wicki AN, Clemetson KJ. Structural of the human blood platelet membrane glycoprotein Ibα gene. Biochem Biophys Res Commun. 1988;156:389–95.CrossRefPubMed
8.
Siaka C, Rugeri L, Caron C, Goudemand J. A new ELISA assay for diagnosis of acquired von Willebrand syndrome. Haemophilia. 2003;9:303–8.CrossRefPubMed
9.
Ulrichts H, Harsfalvi J, Bene L, Matko J, Vermylen J, Ajzenberg N, Baruch D, Deckmyn H, Tornai I. A monoclonal antibody directed against human von Willebrand factor induces type 2B-like alternations. J Thromb Haemost. 2004;2:1622–8.CrossRefPubMed
10.
Depraetere H, Ajzenberg N, Girma JP, Lacombe C, Meyer D, Deckmyn H, Baruch D. Platelet aggregation induced by a monoclonal antibody to the A1 domain of von Willebrand factor. Blood. 1998;91:3792–9.PubMed
Metadata
Title
Type 2B-like acquired von Willebrand syndrome
Authors
Toshio Shigekiyo
Etsuko Sekimoto
Atsuhisa Shirakami
Hiroshi Yamaguchi
Hironobu Shibata
Shuji Ozaki
Kazuya Kanda
Seiya Saito
Nobuo Satake
Osamu Fujino
Publication date
01-10-2011
Publisher
Springer Japan
Published in
International Journal of Hematology / Issue 4/2011
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-011-0938-0

Other articles of this Issue 4/2011

International Journal of Hematology 4/2011 Go to the issue

Letter to the Editor

Attractive tools for systematic case accumulation

Meeting Report

Report of the Fifth Meeting of the International Network for Pediatric Hemophilia: a focus on prophylaxis and immune tolerance induction

Case Report

A new four-way variant t(5;17;15;20)(q33;q12;q22;q11.2) in acute promyelocytic leukemia

Letter to the Editor

Dissociation of ferritin and hepcidin in a case of adult-onset Still’s disease

Progress in Hematology

Novel therapies in MM: from the aspect of preclinical studies

Progress in Hematology

Targeting the interplay between myeloma cells and the bone marrow microenvironment in myeloma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits